FEAF
TPEx

3219 倚強科

108.00 ▲ 4.00 (3.85%) Close · 2026-11-13 · TPEx
Ask about 3219
This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.

Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.

Your risk profile
Conclusion

Mixed picture: 3 strengths against 1 watch-outs. Weigh them against your own goals.

For a moderate profile, none of the items above crosses the watch-out thresholds set by the team.

No model narrative: the model call failed. The structured analysis above is complete on its own.

Strengths

+ Revenue grew 49.7% in 2025; latest quarter Q3 2026: 44.7% year on year. source (Financials) →
+ Return on equity 19.0% with a 15.1% net margin: highly profitable. source (Key Stats) →
+ Free cash flow was positive in 2025: 72 NT$ million. source (Financials) →

Watch-outs

! The current price implies 6.6% perpetual growth, above the 3.5% ceiling: the price already assumes high expectations. source (Valuation) →

What to check before deciding

?Can the company sustain growth above the perpetual-growth ceiling for years?

What the analysis found

! Valuation (DCF) The current price implies 6.6% perpetual growth, above the 3.5% ceiling: the price already assumes high expectations. source →
+ Growth Revenue grew 49.7% in 2025; latest quarter Q3 2026: 44.7% year on year. source →
+ Profitability Return on equity 19.0% with a 15.1% net margin: highly profitable. source →
· Debt Liabilities are 40.3% of total assets (Q3 2026). source →
+ Cash flow Free cash flow was positive in 2025: 72 NT$ million. source →
· Filings 1 verified alert(s); latest on 2026-11-10: 公告本公司115年第3季合併財務報告業經提報董事會通過 source →
· Filings 6 filing(s) are held or rejected and wait for human review. source →